Bristol-Myers Seeks To Bust Genentech Cancer Drug Patents

Law360, New York (May 7, 2013, 10:06 PM EDT) -- Bristol-Myers Squibb Co. on Friday filed suit in California federal court that two Genentech Inc. patents relating to blood cancer treatment are invalid and that Bristol-Myers Squibb's antibody-producing cancer drugs Erbitux and Yervoy do not infringe those patents.

In a complaint, Bristol-Myers Squibb targeted Genentech Inc. and nonprofit cancer treatment center City of Hope, who have allegedly threatened to enforce the two so-called Cabilly patents — named for their inventor, Shmuel Cabilly — which relate to antibody-producing medication. Genentech and City of Hope are co-assignees of...
To view the full article, register now.